Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Blood (2015) 126 (23): 2745.

https://doi.org/10.1182/blood.V126.23.2745.2745

Published: 2015

Journal Articles

Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial

Larysa Sanchez, MD, Yucai Wang, MD PhD, Laura McBride, RN, BSN, OCN, CCRP, Elizabeth Bilotti, MSN, David H. Vesole, MD, Joshua Richter, MD, Noa Biran, MD, Palka Anand, Kristin Ivanovski, Ann McNeill, ANP, David Siegel, MD PhD

Blood (2015) 126 (23): 4264.

https://doi.org/10.1182/blood.V126.23.4264.4264

Published: 2015

Journal Articles

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ajai Chari, MD, Saurabh Chhabra, MD, Saad Usmani, MD, Sarah Larson, MD, Ruben Niesvizky, MD, Jeffrey Matous, MD, Cristina Gasparetto, MD, Beata Holkova, MD, Matthew Lunning, DO, Jason Valent, MD, Larry D. Anderson, Jr., MD PhD, Chatchada Karanes, MD, Long Kwei, PhD, Lipo Chang, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Kevin McDonagh, MD

Blood (2015) 126 (23): 377.

https://doi.org/10.1182/blood.V126.23.377.377

Published: 2015

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

David S. Siegel, MD, PhD, Michael Wang, M.D., Thomas G Martin, III, MD, Jeffrey R. Infante, MD, Jonathan L. Kaufman, MD, Kanya Ranjangam, MD, PhD, Mei Huang, MS, Elizabeth Bilotti, MSN, RN, Ravi Vij, MD

Blood (2012) 120 (21): 2962.

https://doi.org/10.1182/blood.V120.21.2962.2962

Published: 2012

Journal Articles

Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

Joshua R. Richter, MD, Elizabeth Bilotti, MSN, RN, Laura McBride, Linda Schmidt, Zhijie Gao, MD, Madiha Tufail, MD, Palka Anand, Ann McNeill, Urszula Bednarz, Thorsten Graef, MD, PhD, David H. Vesole, MD, PhD, David S. Siegel, MD, PhD

Blood (2011) 118 (21): 3986.

https://doi.org/10.1182/blood.V118.21.3986.3986

Published: 2011

Journal Articles

Unrelated Donor Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Multiple Myeloma: The John Theurer Cancer Center Experience,

Michele L. Donato, MD, David H. Vesole, MD, PhD, David S. Siegel, MD, PhD, Barbara Adler-Brecher, Eiswarya Chichili, MD, Andrew L Pecora, MD, Phyllis McKiernan, APN, Melissa Baker, APN, Themba Nyirenda, PhD, Elizabeth Bilotti, MSN, RN, Andre Goy, MD, Scott D Rowley, MD

Blood (2011) 118 (21): 4162.

https://doi.org/10.1182/blood.V118.21.4162.4162

Published: 2011

Journal Articles

Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma

David Samuel diCapua Siegel, MD, PhD, Laura McBride, Elizabeth Bilotti, MSN, RN, Linda Schmidt, Zhijie Gao, MD, Madiha Tufail, MD, Nikoletta Lendvai, MD, PhD, Ann McNeill, Kristen Donadio, Karly Olivo, Urzula Bednarz, Thorsten Graef, MD, PhD, David H. Vesole, MD, PhD

Blood (2010) 116 (21): 3065.

https://doi.org/10.1182/blood.V116.21.3065.3065

Published: 2010

NARROW

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

A Phase 2 Study of Prolonged Carfilzomib Therapy in Patients with Multiple Myeloma Previously Enrolled in Carfilzomib Clinical Trials.

Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

Unrelated Donor Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Multiple Myeloma: The John Theurer Cancer Center Experience,

Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only